Limitations, agreements, and source contact

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Source last updated 2022-04-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

miwang@mdanderson.org

organization

UT MD Anderson Cancer Center

phone

(713) 792-2860

title

Michael Wang, MD, Professor, Lymphoma-Myeloma

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice